RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE

Special systems were developed for response assessment of immunooncology drugs. The role and benefits of particular system in assessing the efficacy of different immunotherapy methods are not clear yet. The objective of this study is to compare the responses on ipilimab (IPI) or dendritic cell vacci...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Novik, E. V. Yaremenko, E. M. Anokhina, T. L. Nehaeva, A. I. Semenova, D. Kh. Latipova, S. A. Protsenko, I. A. Baldueva
Format: Artigo
Language:Russo
Published: Tomsk National Research Medical Center of the Russian Academy of Sciences 2019-09-01
Series:Sibirskij Onkologičeskij Žurnal
Subjects:
melanoma
ipilimumab
dendritic cell vaccines
recist 1.1
irrc
response assessment
immunotherapy
Online Access:https://www.siboncoj.ru/jour/article/view/1136
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items